

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

# SAFETY DATA SHEET

FRS-40 SEMI-GLOSS BASE GREY S7000-N/B053

## SECTION 1: Identification of the substance/mixture and of the company/ undertaking

Product name SDS code : FRS-40 SEMI-GLOSS BASE GREY S7000-N/B053 : 4092B053B

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

	Identified uses	
Paint. Professional use Industrial use		
	Uses advised against	
All other uses		
Braduat usa	. Solvent borne costing for interior use	

Product use

: Solvent borne coating for interior use.

### 1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

responsible for this SDS

### 1.4 Emergency telephone number

National advisory body/Poison Center				
Telephone number	: +43 1 406 43 43			
<u>Supplier</u>				
Telephone number	: +33 (0)5 34 01 34 01 +33 (0)5 61 60 23 30			
Hours of operation	:			

## **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

Product definition : Mixture

### Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H336 STOT RE 2, H373

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	1/19	AkzoNobel

## **SECTION 2: Hazards identification**

See Section 11 for more detailed information on health effects and symptoms.

2

### 2.2 Label elements

Hazard pictograms



Signal word	:	Warning
Hazard statements	:	Flammable liquid and vapor. Causes skin irritation. Causes serious eye irritation. May cause drowsiness or dizziness. May cause damage to organs through prolonged or repeated exposure.
Precautionary statements		
Prevention	:	Wear protective gloves. Wear eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Do not breathe vapor. Wash hands thoroughly after handling.
Response	:	Get medical advice or attention if you feel unwell. IF INHALED: Call a POISON CENTER or doctor if you feel unwell. Take off contaminated clothing and wash it before reuse. IF ON SKIN: Wash with plenty of water. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.
Storage	:	Store in a well-ventilated place. Keep container tightly closed. Keep cool.
Disposal	:	Dispose of contents and container in accordance with all local, regional, national and international regulations.
Hazardous ingredients	:	n-butyl acetate Reaction mass of ethylbenzene and xylene
Supplemental label elements	:	Contains methyl methacrylate. May produce an allergic reaction. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	Not applicable.
Special packaging requirem	en	<u>ts</u>
Containers to be fitted with child-resistant fastenings	:	Not applicable.
Tactile warning of danger	:	Not applicable.
2.3 Other hazards		
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do not result in classification	:	None known.



Product/ingredient name	Identifiers	%	Regulation (EC) No. 1272/2008 [CLP]	Туре
-butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1	≥10 - ≤25	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	[1] [2]
Reaction mass of ethylbenzene and xylene	REACH #: 01-2119488216-32	≥10 - <20	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
2-methoxy-1-methylethyl acetate	REACH #: 01-2119475791-29 EC: 203-603-9 CAS: 108-65-6	≤10	Flam. Liq. 3, H226 STOT SE 3, H336	[1] [2]
methyl methacrylate	REACH #: 01-2119452498-28 EC: 201-297-1 CAS: 80-62-6 Index: 607-035-00-6	≤0.3	Flam. Liq. 2, H225 Skin Irrit. 2, H315 Skin Sens. 1, H317 STOT SE 3, H335	[1] [2]
cyclohexanone	REACH #: 01-2119453616-35 CAS: 108-94-1 Index: 606-010-00-7	≤0.3	Flam. Liq. 3, H226 Acute Tox. 4, H332	[1] [2]
Hydrocarbons, C11-C14, n- alkanes, isoalkanes, cyclics, <2% aromatics	REACH #: 01-2119456620-43 EC: 926-141-6	≤0.3	Asp. Tox. 1, H304 EUH066	[1]
			See Section 16 for the full text of the H statements declared above.	

## **SECTION 3: Composition/information on ingredients**

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII

[4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

[5] Substance of equivalent concern

[6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.



## **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

Eye contact	:	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
Inhalation	:	Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Skin contact	:	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse.
Ingestion	:	Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
Protection of first-aiders	:	No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

### 4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains methyl methacrylate. May produce an allergic reaction.

### Over-exposure signs/symptoms

:	Adverse symptoms may include the t pain or irritation watering redness
	redness
	:

following:



# SECTION 4: First aid measures

Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.

### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	<ul> <li>Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.</li> </ul>
Specific treatments	: No specific treatment.

## **SECTION 5: Firefighting measures**

e_eg.	.9
5.1 Extinguishing media	
Suitable extinguishing media	Use dry chemical, CO <sub>2</sub> , water spray (fog) or foam.
Unsuitable extinguishing media	Do not use water jet.
5.2 Special hazards arising	n the substance or mixture
Hazards from the substance or mixture	Flammable liquid and vapor. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, w the risk of a subsequent explosion.
Hazardous combustion products	Decomposition products may include the following materials: carbon dioxide carbon monoxide halogenated compounds metal oxide/oxides
5.3 Advice for firefighters	
Special protective actions for fire-fighters	Promptly isolate the scene by removing all persons from the vicinity of the incident there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Special protective equipment for fire-fighters	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection fo chemical incidents.

## **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition source No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.	
For emergency responders	: If specialized clothing is required to de information in Section 8 on suitable ar information in "For non-emergency pe	d unsuitable materials. See also the
Date of issue/Date of revision	: 2-11-2022	Version : 1.01
Date of previous issue	: 1-10-2022	5/19 AkzoNobel

### **SECTION 6: Accidental release measures**

6.2 Environmental precautions	:	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and materials for	or c	ontainment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	:	Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.
6.4 Reference to other sections	:	See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

## **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Do not breathe vapor or mist. Do not ingest. Avoid contact with eyes, skin and clothing. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

### Seveso Directive - Reporting thresholds

### Danger criteria

Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	6/19	AkzoNobel

S	ECTION 7: Handling and storage		
		Notification and MAPP threshold	Safety report threshold
	P5c	5000 tonne	50000 tonne

### 7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific solutions	: Not available.

## **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

### 8.1 Control parameters

Occupational exposure limits			
-butyl acetate		Regulation on Limit Values - MAC (Austria CEIL: 480 mg/m <sup>3</sup> 15 minutes. CEIL: 100 ppm 15 minutes. TWA: 480 mg/m <sup>3</sup> 8 hours. TWA: 100 ppm 8 hours.	ı, 9/2018).
Reaction mass of ethylbenzene	and xylene	Regulation on Limit Values - MAC (Austria through skin. PEAK: 442 mg/m <sup>3</sup> , 4 times per shift, 15 min PEAK: 100 ppm, 4 times per shift, 15 minut TWA: 221 mg/m <sup>3</sup> , 4 times per shift, 8 hours TWA: 50 ppm, 4 times per shift, 8 hours.	utes. tes.
2-methoxy-1-methylethyl aceta	e	Regulation on Limit Values - MAC (Austria through skin. TWA: 50 ppm 8 hours. TWA: 275 mg/m <sup>3</sup> 8 hours. CEIL: 100 ppm, 8 times per shift, 5 minutes CEIL: 550 mg/m <sup>3</sup> , 8 times per shift, 5 minutes	5.
methyl methacrylate		Regulation on Limit Values - MAC (Austria sensitizer. CEIL: 420 mg/m <sup>3</sup> , 8 times per shift, 5 minut CEIL: 100 ppm, 8 times per shift, 5 minutes TWA: 210 mg/m <sup>3</sup> , 8 times per shift, 8 hours TWA: 50 ppm, 8 times per shift, 8 hours.	es. S.
cyclohexanone		Regulation on Limit Values - MAC (Austria through skin. PEAK: 80 mg/m <sup>3</sup> , 4 times per shift, 15 minute PEAK: 20 ppm, 4 times per shift, 15 minute TWA: 20 mg/m <sup>3</sup> , 2 times per shift, 8 hours. TWA: 5 ppm, 2 times per shift, 8 hours.	ites.
Recommended monitoring : procedures	atmosphere o of the ventilati protective equ the following: the assessme limit values an atmospheres of exposure to (Workplace at for the measu	contains ingredients with exposure limits, perso r biological monitoring may be required to detern on or other control measures and/or the necess ipment. Reference should be made to monitori European Standard EN 689 (Workplace atmos int of exposure by inhalation to chemical agents ad measurement strategy) European Standard I - Guide for the application and use of procedure o chemical and biological agents) European Sta tmospheres - General requirements for the perfor rement of chemical agents) Reference to nation r methods for the determination of hazardous su	mine the effectiveness ity to use respiratory ng standards, such as pheres - Guidance for for comparison with EN 14042 (Workplace is for the assessment indard EN 482 ormance of procedures nal guidance
Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	:1-10-2022	7/19	AkzoNobel

## **SECTION 8: Exposure controls/personal protection**

## required.

Product/ingredient name	Туре	Exposure	Value	Population	Effects
p-butyl acetate	DNEL	Long term Oral	3.4 mg/kg	General	Systemic
		Law a tama Dama d	bw/day	population	C. untermin
	DNEL	Long term Dermal	3.4 mg/kg bw/day	General population	Systemic
	DNEL	Long term Dermal	7 mg/kg	Workers	Systemic
		g	bw/day		
	DNEL	Long term	12 mg/m <sup>3</sup>	General	Systemic
		Inhalation	10	population	
	DNEL	Long term Inhalation	48 mg/m³	Workers	Systemic
	DNEL	Long term	102.34 mg/	General	Local
		Inhalation	m³ Ö	population	
	DNEL	Long term	480 mg/m³	Workers	Local
		Inhalation	050 7	0	
	DNEL	Short term Inhalation	859.7 mg/ m³	General population	Local
	DNEL	Short term	859.7 mg/	General	Systemic
		Inhalation	m <sup>3</sup>	population	
	DNEL	Short term	960 mg/m <sup>3</sup>	Workers	Local
		Inhalation	000 / 3	\ <b>\</b> / <b>a</b> w/ <b>c</b> ===	C. at a set of
	DNEL	Short term Inhalation	960 mg/m <sup>3</sup>	Workers	Systemic
Reaction mass of ethylbenzene and	DNEL	Long term Oral	1.6 mg/kg	General	Systemic
xylene			bw/day	population	- , - , - , - , - , - , - , - , - , - ,
	DNEL	Long term	14.8 mg/m <sup>3</sup>	General	Systemic
		Inhalation	/ 2	population	
	DNEL	Long term	77 mg/m³	Workers	Systemic
	DNEL	Inhalation Long term Dermal	108 mg/kg	General	Systemic
	DINCE		bw/day	population	Gysternie
	DNEL	Long term Dermal	180 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Inhalation	289 mg/m <sup>3</sup>	Workers	Local
	DNEL	Short term	289 mg/m <sup>3</sup>	Workers	Systemic
		Inhalation			-,
methyl methacrylate	DNEL	Long term Dermal	8.2 mg/kg	General	Systemic
			bw/day	population	Constant.
	DNEL	Long term Dermal	13.67 mg/ kg bw/day	Workers	Systemic
	DNEL	Long term	74.3 mg/m <sup>3</sup>	General	Systemic
		Inhalation		population	
	DNEL	Long term	104 mg/m <sup>3</sup>	General	Local
	DNEL	Inhalation	208 ma/m3	population Workers	Local
	DINEL	Long term Inhalation	208 mg/m <sup>3</sup>	VVUINEIS	LUCAI
	DNEL	Long term	208 mg/m <sup>3</sup>	Workers	Systemic
		Inhalation	-		
cyclohexanone	DNEL	Short term Dermal	1 mg/kg	General	Systemic
	DNEL	Long term Dermal	bw/day 1 mg/kg	population General	Systemic
			bw/day	population	Cysternic
	DNEL	Short term Oral	1.5 mg/kg	General	Systemic
			bw/day	population	
	DNEL	Long term Oral	1.5 mg/kg	General	Systemic
		Short term Dermal	bw/day 4 mg/kg	population Workers	Systemic
	DNEL		+ mg/kg	Wontoro	oyotonno
e of issue/Date of revision : 2-11-			Version	: 1.01	

## **SECTION 8: Exposure controls/personal protection**

SECTION 0. Exposure conti	1013/p		Clion		
	DNEL	Long term Dermal	bw/day 4 mg/kg bw/day	Workers	Systemic
	DNEL	Long term Inhalation	10 mg/m³	General population	Systemic
	DNEL	Long term Inhalation	20 mg/m³	General population	Local
	DNEL	Short term Inhalation	20 mg/m³	General population	Systemic
	DNEL	Short term Inhalation	40 mg/m³	General population	Local
	DNEL	Long term Inhalation	40 mg/m <sup>3</sup>	Workers	Local
	DNEL	Long term Inhalation	40 mg/m³	Workers	Systemic
	DNEL	Short term Inhalation	80 mg/m³	Workers	Local
	DNEL	Short term Inhalation	80 mg/m³	Workers	Systemic

#### **PNECs**

No PNECs available.

8.2 Exposure controls				
Appropriate engineering controls	:	ventilation or other engine contaminants below any controls also need to kee	entilation. Use process enclos eering controls to keep worker recommended or statutory limit p gas, vapor or dust concentra losion-proof ventilation equipm	exposure to airborne s. The engineering tions below any lower
Individual protection meas	ures			
Hygiene measures	:	before eating, smoking a Appropriate techniques s Wash contaminated cloth	nd face thoroughly after handlir nd using the lavatory and at the hould be used to remove poten ing before reusing. Ensure tha to the workstation location.	e end of the working period. tially contaminated clothing.
Eye/face protection	:	assessment indicates this gases or dusts. If contact	g with an approved standard sh s is necessary to avoid exposur t is possible, the following prote idicates a higher degree of prot	re to liquid splashes, mists, ection should be worn,
Skin protection				
Hand protection	:	be worn at all times when this is necessary. Consid check during use that the should be noted that the different for different glow	rvious gloves complying with an handling chemical products if lering the parameters specified gloves are still retaining their p time to breakthrough for any glo e manufacturers. In the case o protection time of the gloves ca	a risk assessment indicates by the glove manufacturer, protective properties. It ove material may be of mixtures, consisting of
		protection class of 6 (brear recommended. Recomm When only brief contact is (breakthrough time >30 n Recommended gloves: N	ently repeated contact may occ akthrough time >480 minutes a nended gloves: Viton $\circledast$ or Nitrile s expected, a glove with protec ninutes according to EN374) is litrile, thickness $\ge 0.12$ mm. ed regularly and if there is any s	ccording to EN374) is e, thickness ≥ 0.38 mm. tion class of 2 or higher recommended.
		The performance or effect	tiveness of the glove may be r	educed by physical/
Date of issue/Date of revision		: 2-11-2022	Version : 1.01	
Date of previous issue		: 1-10-2022	9/19	AkzoNobel

## **SECTION 8: Exposure controls/personal protection**

		chemical damage and poor maintenance.
		The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.
Body protection	:	Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	:	Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	:	Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
Environmental exposure controls	:	Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

## **SECTION 9: Physical and chemical properties**

9.1 Information on basic physical and chemical properties

#### **Appearance Physical state** : Liquid. Color : Gray. Odor : Characteristic. : Not available. Odor threshold pН : Not available. Melting point/freezing point : Not available. Initial boiling point and : Not available. boiling range : Closed cup: 28°C Flash point : Not available. **Evaporation rate** : Not available. Flammability (solid, gas) Upper/lower flammability or : Not available. explosive limits Vapor pressure : Not available. : Highest known value: 4.6 (Air = 1) (2-methoxy-1-methylethyl acetate). Vapor density Weighted average: 4.02 (Air = 1) : 1.329 g/cm<sup>3</sup> Density Solubility(ies) : Insoluble in the following materials: cold water. Partition coefficient: n-octanol/ : Not available. water Auto-ignition temperature : Not available. **Decomposition temperature** : Not available. Viscosity : Kinematic (room temperature): 8.28 cm<sup>2</sup>/s Kinematic (40°C): 1.01 cm<sup>2</sup>/s



# **SECTION 10: Stability and reactivity**

10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.
10.5 Incompatible materials	: Reactive or incompatible with the following materials: oxidizing materials
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

### Acute toxicity

prbutyl acetate LC50 Inhalation Gas. LC50 Inhalation Vapor LC50 Inhalation Vapor LC50 Inhalation Vapor LD50 Dermal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LC50 Inhalation Gas. ethylbenzene and xylene methyl methacrylate LC50 Inhalation Vapor tLC50 Inhalation Vapor LC50 Intraperitoneal LD50 Intraperitoneal LD50 Intraperitoneal LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Oral LD50 Subcutaneous LD50 Subcutaneous LD50 Subcutaneous LD50 Intraperitoneal LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50 Intraperitoneal Rat LD50	Product/ingredient name	Result	Species	Dose	Exposure
LC50 Inhalation Vapor     Mouse     6 g/m³     2 hours       LD50 Dermal     Rabbit     >17600 mg/kg     -       LD50 Oral     Guinea pig     4700 mg/kg     -       LD50 Oral     Mouse     6 g/kg     -       LD50 Oral     Mouse     6 g/kg     -       LD50 Oral     Rabbit     3200 mg/kg     -       LD50 Oral     Rabbit     3200 mg/kg     -       LD50 Oral     Rat     10768 mg/kg     -       LD50 Oral     Rat     10768 mg/kg     -       LD50 Oral     Rat     5000 ppm     4 hours       Ethylbenzene and xylene     LC50 Inhalation Vapor     Mouse     18500 mg/m³     2 hours       LD50 Dermal     Ratbit     >5 g/kg     -     -       LD50 Intraperitoneal     Guinea pig     1890 mg/kg     -       LD50 Intraperitoneal     Mouse     3625 mg/kg     -       LD50 Varal     Guinea pig     5954 mg/kg     -       LD50 Subcutaneous     Guinea pig     5954 mg/kg     -       LD50 Intraperitoneal     Rat     7088 mg/kg     -       LD50 Subcutaneous     Rat     7088 mg/kg     -       LD50 Subcutaneous     Rat     7088 mg/kg     -       LD50 Intraperitoneal     Guinea pig	p-butyl acetate	LC50 Inhalation Gas.	Rat	390 ppm	4 hours
LD50 Dermal LD50 IntraperitonealRabbit>17600 mg/kg-LD50 Intraperitoneal LD50 OralMouse1230 mg/kg-LD50 Oral LD50 OralMouse6 g/kg-LD50 Oral LD50 OralRabbit3200 mg/kg-LD50 Oral LD50 OralRat10768 mg/kg-LD50 Oral LD50 OralRat10768 mg/kg-LC50 Inhalation Gas.Rat78000 mg/m³4 hoursLC50 Inhalation Vapor LD50 IntraperitonealMouse18500 mg/m³2 hoursLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig1900 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse945 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 SubcutaneousMouse3625 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7872 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1230 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg- </td <td>, ,</td> <td>LC50 Inhalation Vapor</td> <td>Mouse</td> <td></td> <td>2 hours</td>	, ,	LC50 Inhalation Vapor	Mouse		2 hours
LD50 Intraperitoneal LD50 OralMouse Guinea pig Guinea pig 4700 mg/kg-Reaction mass of ethylbenzene and xylene methyl methacrylateLC50 Inhalation Gas.Rat10768 mg/kg-LC50 Inhalation Gas.Rat10768 mg/kgLC50 Inhalation Gas.Rat78000 mg/m³2 hoursLC50 Inhalation Vapor LC50 Inhalation VaporRat78000 mg/m³4 hoursLC50 Inhalation Vapor LD50 DermalGuinea pig Guinea pig1890 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig945 mg/kg-LD50 Oral LD50 IntraperitonealRat1328 mg/kg-LD50 Oral LD50 OralGuinea pig Guinea pig5954 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Subcutaneous LD50 SubcutaneousGuinea pig Guinea pig5954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7808 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Subcutaneous LD50 IntraperitonealGuinea pig Guinea pig930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg </td <td></td> <td>LD50 Dermal</td> <td>Rabbit</td> <td></td> <td>-</td>		LD50 Dermal	Rabbit		-
LD50 OralGuinea pig Mouse4700 mg/kg G /kg-LD50 OralLD50 OralRabbit3200 mg/kg-LD50 OralRat10768 mg/kg-LD50 OralRat10768 mg/kg-LD50 OralRat5000 ppm4 hoursethylbenzene and xyleneLC50 Inhalation VaporMouse18500 mg/m³2 hoursLC50 Inhalation VaporRat78000 mg/m³4 hoursLC50 Inhalation VaporRat78000 mg/m³4 hoursLD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRatit1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitone		LD50 Intraperitoneal	Mouse		-
LD50 Oral LD50 OralMouse6 g/kg-Reaction mass of ethylbenzene and xylene methyl methacrylateLC50 Inhalation Gas.Rat10768 mg/kg-LC50 Inhalation Vapor LD50 DermalMouse18500 mg/m³2 hoursLC50 Inhalation Vapor LD50 DermalRat78000 mg/m³4 hoursLC50 Inhalation Vapor LD50 IntraperitonealRat>5 g/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig1890 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1328 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Oral LD50 OralRat7872 mg/kg-LD50 Oral LD50 SubcutaneousRat7088 mg/kg-LD50 Subcutaneous LD50 SubcutaneousMouse5954 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig930 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat </td <td></td> <td></td> <td>Guinea pig</td> <td>4700 mg/kg</td> <td>-</td>			Guinea pig	4700 mg/kg	-
LD50 Oral LD50 Oral LD50 Oral ethylbenzene and xylene methyl methacrylateLD50 Oral LC50 Inhalation Gas.Rat10768 mg/kg 5000 ppm-LC50 Inhalation Vapor LC50 Inhalation VaporMouse18500 mg/m³2 hoursLC50 Inhalation Vapor LD50 DermalRat78000 mg/m³4 hoursLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Guinea pig5954 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 IntraperitonealRat1328 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 OralMouse3625 mg/kg-LD50 Oral LD50 SubcutaneousRat7872 mg/kg-LD50 Subcutaneous LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 SubcutaneousRat7088 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealGuinea pig S954 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealMouse1230 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperitoneal LD50 IntraperitonealRat1130 mg/kg-LD50 Intrap		LD50 Oral			-
Reaction mass of ethylbenzene and xylene methyl methacrylateLD50 Oral LC50 Inhalation Gas.Rat10768 mg/kg s000 ppm4 hoursLC50 Inhalation Gas.Rat5000 ppm4 hoursLC50 Inhalation Vapor LD50 IntraperitonealMouse18500 mg/m³2 hoursLD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealRat7088 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1		LD50 Oral	Rabbit		-
Reaction mass of ethylbenzene and xylene methyl methacrylateLC50 Inhalation Gas.Rat5000 ppm4 hoursLC50 Inhalation Vapor LD50 Intraperitoneal LD50 IntraperitonealMouse18500 mg/m³2 hoursLD50 Intraperitoneal LD50 IntraperitonealGuinea pig Rat1890 mg/kg-LD50 Intraperitoneal 		LD50 Oral	Rat	10768 mg/kg	-
methyl methacrylateLC50 Inhalation Vapor LC50 Inhalation Vapor LD50 DermalMouse18500 mg/m³2 hoursLD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRat7870 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 IntraperitonealRabbit1 mL/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 Intraperi		LC50 Inhalation Gas.	Rat		4 hours
LC50Inhalation VaporRat78000 mg/m³4 hoursLD50DermalRabbit>5 g/kg-LD50IntraperitonealGuinea pig1890 mg/kg-LD50IntraperitonealMouse945 mg/kg-LD50IntraperitonealRat1328 mg/kg-LD50OralGuinea pig5954 mg/kg-LD50OralGuinea pig5954 mg/kg-LD50OralMouse3625 mg/kg-LD50OralRat7872 mg/kg-LD50OralRat7872 mg/kg-LD50SubcutaneousMouse5954 mg/kg-LD50SubcutaneousMouse5954 mg/kg-LD50SubcutaneousRat7088 mg/kg-LD50SubcutaneousRat7088 mg/kg-LD50IntraperitonealGuinea pig930 mg/kg-LD50IntraperitonealGuinea pig930 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealMouse1230 mg/kg-LD50IntraperitonealRabbit1540 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1300 mg/kg-LD50IntraperitonealRat1130 mg/kg-LD50IntraperitonealRat1		LC50 Inhalation Vapor	Mouse	18500 ma/m <sup>3</sup>	2 hours
LD50 DermalRabbit>5 g/kg-LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 DermalRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-<	, ,		Rat		4 hours
LD50 IntraperitonealGuinea pig1890 mg/kg-LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRat1130 mg/kg-					-
LD50 IntraperitonealMouse945 mg/kg-LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 DermalRat7088 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1130 mg/kg-LD50 Oral<			Guinea pig		-
LD50 IntraperitonealRat1328 mg/kg-LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 OralGuinea pig5954 mg/kg-LD50 OralMouse3625 mg/kg-LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat100 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 Oral Mouse 3625 mg/kg - LD50 Oral Rabbit 8700 mg/kg - LD50 Oral Rat 7872 mg/kg - LD50 Subcutaneous Guinea pig 5954 mg/kg - LD50 Subcutaneous Mouse 5954 mg/kg - LD50 Subcutaneous Rat 7088 mg/kg - LD50 Subcutaneous Rat 8000 ppm 4 hours LD50 Dermal Rabbit 1 mL/kg - LD50 Dermal Guinea pig 930 mg/kg - LD50 Intraperitoneal Guinea pig 930 mg/kg - LD50 Intraperitoneal Mouse 1230 mg/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rabbit 1540 mg/kg - LD50 Intraperitoneal Rat 1130 mg/kg -			Guinea pig		-
LD50 OralRabbit8700 mg/kg-LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 OralRat7872 mg/kg-LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 SubcutaneousGuinea pig5954 mg/kg-LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LD50 SubcutaneousRat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 SubcutaneousMouse5954 mg/kg-LD50 SubcutaneousRat7088 mg/kg-LC50 Inhalation Gas.Rat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 SubcutaneousRat7088 mg/kg-LC50 Inhalation Gas.Rat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1240 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
cyclohexanoneLC50 Inhalation Gas.Rat8000 ppm4 hoursLD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1800 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-			Rat		-
LD50 DermalRabbit1 mL/kg-LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1400 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-	cyclohexanone	LC50 Inhalation Gas.	Rat		4 hours
LD50 IntraperitonealGuinea pig930 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1400 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-		LD50 Dermal	Rabbit		-
LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-		LD50 Intraperitoneal	Guinea pig		-
LD50 IntraperitonealMouse1230 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-					-
LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-			Mouse		-
LD50 IntraperitonealRabbit1540 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-			Rabbit		-
LD50 IntraperitonealRat1130 mg/kg-LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-			Rabbit		-
LD50 IntraperitonealRat1130 mg/kg-LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-			Rat		-
LD50 OralMouse1400 mg/kg-LD50 OralRat1800 mg/kg-LD50 OralRat1620 uL/kg-				1130 mg/kg	-
LD50 Oral Rat 1800 mg/kg - LD50 Oral Rat 1620 uL/kg -			Mouse		-
LD50 Oral Rat 1620 uL/kg -			Rat		-
					-
					-
e of issue/Date of revision : 2-11-2022 Version : 1.01			•	·	•

11/19



## **SECTION 11: Toxicological information**

#### : Not available. **Conclusion/Summary**

Irritation/Corrosion					
Product/ingredient name	Result	Species	Score	Exposure	Observation
<b>p</b> -butyl acetate	Eyes - Moderate irritant	Rabbit	-	100 mg	-
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
Reaction mass of	Eyes - Mild irritant	Rabbit	-	mg 87 mg	-
ethylbenzene and xylene	5			Ŭ	
	Eyes - Severe irritant	Rabbit	-	24 hours 5 mg	-
	Skin - Mild irritant	Rat	-	8 hours 60 UI	
	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
	Skin - Moderate irritant	Rabbit	-	100 %	-
cyclohexanone	Eyes - Severe irritant	Rabbit	-	24 hours 250	-
				ug	
	Eyes - Severe irritant Skin - Mild irritant	Rabbit Rabbit	-	20 mg 500 mg	-
Conclusion/Summary	: Not available.			eeeg	
Conclusion/Summary	. Not available.				
<u>Sensitization</u>					
Conclusion/Summary	: Not available.				
<u>Mutagenicity</u>					
Conclusion/Summary	: Not available.				
<u>Carcinogenicity</u>					
<b>Conclusion/Summary</b>	: Not available.				
Reproductive toxicity					
Conclusion/Summary	: Not available.				
<u>Teratogenicity</u>					
Conclusion/Summary	: Not available.				

### Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
<b>n</b> -butyl acetate Reaction mass of ethylbenzene and xylene	Category 3 Category 3	-	Narcotic effects Respiratory tract irritation
2-methoxy-1-methylethyl acetate methyl methacrylate	Category 3 Category 3	-	Narcotic effects Respiratory tract irritation

### Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Reaction mass of ethylbenzene and xylene	Category 2	-	-

### Aspiration hazard

Product/ingredient name	Result	
Reaction mass of ethylbenzene and xylene Hydrocarbons, C11-C14, n-alkanes, isoalkanes, cyclics, <2% aromatics	ASPIRATION HAZARD - Category 1 ASPIRATION HAZARD - Category 1	

#### Information on the likely : Not available. routes of exposure



## **SECTION 11: Toxicological information**

SECTION 11: Toxico	ogical information
Potential acute health effects	
Eye contact	: Causes serious eye irritation.
Inhalation	: Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness.
Skin contact	: Causes skin irritation.
Ingestion	: Can cause central nervous system (CNS) depression.
Symptoms related to the phy	sical, chemical and toxicological characteristics
Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.
Delayed and immediate effect	ts and also chronic effects from short and long term exposure
Short term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Long term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Potential chronic health eff	ects
Not available.	
Conclusion/Summary	: Not available.
General	: May cause damage to organs through prolonged or repeated exposure.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.
Other information	: Not available.

## **SECTION 12: Ecological information**

### 12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is not classified as hazardous to the environment, but contains substance(s) hazardous to the environment. See section 3 for details.

Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	13/19	AkzoNobel

## **SECTION 12: Ecological information**

Product/ingredient name	Result	Species	Exposure
n-butyl acetate	Acute LC50 32 mg/l Marine water	Crustaceans - Artemia salina	48 hours
-	Acute LC50 100000 µg/l Fresh water	Fish - Lepomis macrochirus	96 hours
	Acute LC50 18000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 185000 µg/l Marine water	Fish - Menidia beryllina	96 hours
	Acute LC50 62000 µg/l Fresh water	Fish - Danio rerio	96 hours
Reaction mass of ethylbenzene and xylene	Acute LC50 13400 µg/l Fresh water	Fish - Pimephales promelas	96 hours
methyl methacrylate	Acute LC50 191000 µg/l Fresh water	Fish - Lepomis macrochirus - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Acute LC50 159100 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 160200 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 150000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours
	Acute LC50 130000 µg/l Fresh water	Fish - Pimephales promelas - Adult	96 hours
cyclohexanone	Acute EC50 32.9 mg/l Fresh water	Algae - Chlamydomonas reinhardtii - Exponential growth phase	72 hours
	Acute LC50 630000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 527000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 732000 µg/l Fresh water	Fish - Pimephales promelas	96 hours

Conclusion/Summary

: Not available.

### 12.2 Persistence and degradability

**Conclusion/Summary** : Not available.

### 12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
-butyl acetate	2.3	-	low
Reaction mass of ethylbenzene and xylene	3.12	8.1 to 25.9	low
2-methoxy-1-methylethyl acetate	1.2	-	low
methyl methacrylate cyclohexanone	1.38 0.86	- -	low low

### 12.4 Mobility in soil

Soil/water partition coefficient (K <sub>oc</sub> )	: Not available.
Mobility	: Not available.

### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

**12.6 Other adverse effects** : No known significant effects or critical hazards.



## **SECTION 13: Disposal considerations**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 13.1 Waste treatment methods

<u>Product</u>	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
Disposal considerations	: Do not allow to enter drains or watercourses. Dispose of according to all federal, state and local applicable regulations. If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned. For further information, contact your local waste authority.

### European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

Waste code	Waste designation
EWC 08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances
Packaging	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Disposal considerations	<ul> <li>Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions.</li> </ul>
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

## **SECTION 14: Transport information**

	ADR/RID	IMDG		ΙΑΤΑ
14.1 UN number	UN1263	UN1263	UN1263	
14.2 UN proper shipping name	PAINT	PAINT	PAINT	
14.3 Transport hazard class(es)	3	3	3	
14.4 Packing group				
Date of issue/Date of rev	rision : 2-11-2022	Versic	on :1.01	
Date of previous issue	: 1-10-2022	15/19		AkzoNobel

SECTION 14: Transport information						
14.5 Environmental hazards	No.			No.	No.	
Additional informat	ion					
ADR/RID		:	-	50 L according to 2.2.3.1.5.1.	uid is not subject to regulation in	
IMDG		:	<b>Emergency schedules</b> F-E, _S-E_ <b><u>Viscous liquid exception</u></b> This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.3.2.5.			
14.6 Special precautions for user		:	<b>Transport within user's premises:</b> always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.			
14.7 Transport in bu according to IMO instruments	ılk	:	Not applicable.			
SECTION 15: Regulatory information						
15.1 Safety, health a EU Regulation (EC)			-	egislation specific for the sub	ostance or mixture	
	<u>f substan</u>	ces	<u>s subject to author</u>	<u>ization</u>		
Annex XIV						

None of the components are listed.

### Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions : Not applicable. on the manufacture, placing on the market

and use of certain dangerous substances, mixtures and articles

**Other EU regulations** 

voc

The provisions of Directive 2004/42/EC on VOC apply to this product. Refer to the product label and/or technical data sheet for further information.
 -Use : Not applicable.

VOC for Ready-for-Use Mixture	:	Not applicable
Industrial emissions (integrated pollution prevention and control) - Air	:	Not listed

Industrial emissions : Not listed

(integrated pollution prevention and control) -

Water

### Ozone depleting substances (1005/2009/EU)

Not listed.

### Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

### Seveso Directive

Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	16/19	AkzoNobel

### SECTION 15: Regulatory information This product is controlled under the Seveso Directive. Danger criteria Category P5c National regulations Industrial use : The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work. VbF class : A II Very dangerous flammable liquid. Limitation of the use of : Permitted. organic solvents International regulations Chemical Weapon Convention List Schedules I, II & III Chemicals Not listed. **Montreal Protocol** Not listed. Stockholm Convention on Persistent Organic Pollutants Not listed. **Rotterdam Convention on Prior Informed Consent (PIC)** Not listed. **UNECE Aarhus Protocol on POPs and Heavy Metals** Not listed. Inventory list : Not determined. Europe **15.2 Chemical Safety** : No Chemical Safety Assessment has been carried out. Assessment **SECTION 16: Other information** Indicates information that has changed from previously issued version. Abbreviations and : ATE = Acute Toxicity Estimate

acronyms	CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.
-	1272/2008]
	DMEL = Derived Minimal Effect Level
	DNEL = Derived No Effect Level
	EUH statement = CLP-specific Hazard statement
	N/A = Not available
	PBT = Persistent, Bioaccumulative and Toxic
	PNEC = Predicted No Effect Concentration
	RRN = REACH Registration Number
	SGG = Segregation Group
	vPvB = Very Persistent and Very Bioaccumulative

### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]



SECTION 16: Other info	
Class	ification Justification
Flam. Liq. 3, H226	On basis of test data
Skin Irrit. 2, H315	Calculation method
Eye Irrit. 2, H319	Calculation method
STOT SE 3, H336	Calculation method
STOT RE 2, H373	Calculation method
Full text of abbreviated H statem	ents
H225	Highly flammable liquid and vapor.
H226	Flammable liquid and vapor.
H304	May be fatal if swallowed and enters airways.
H312	Harmful in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H332	Harmful if inhaled.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H373	May cause damage to organs through prolonged or repeated exposure.
H412	Harmful to aquatic life with long lasting effects.
EUH066	Repeated exposure may cause skin dryness or cracking.
Full text of classifications [CLP/0	<u>GHS]</u>
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatia Chrania 2	ACULATIC HAZARD (LONIC TERM) Cotogon (2)

Date of issue/ Date of	• 2 November 2022
Date of printing	: 2 November 2022
STOT SE 3	EXPOSURE) - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) - Category 3
STOT RE 2	SPECIFIC TARGET ORGAN TOXICITY (REPEATED
Skin Sens. 1	SKIN SENSITIZATION - Category 1
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Flam. Liq. 3	FLAMMABLE LIQUIDS - Category 3
Flam. Liq. 2	FLAMMABLE LIQUIDS - Category 2
Eye Irrit. 2	SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2
Asp. Tox. 1	ASPIRATION HAZARD - Category 1
Aquatic Chronic 3	AQUATIC HAZARD (LONG-TERM) - Category 3
Acute Tox. 4	ACUTE TOXICITY - Category 4

:	2 November 2022
:	1 October 2022
:	1.01
:	
	:

### Notice to reader

#### FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Date of issue/Date of revision	: 2-11-2022	Version : 1.01	
Date of previous issue	: 1-10-2022	18/19	AkzoNobe

## **SECTION 16: Other information**

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.

